Hotspots and frontiers of cirrhosis with portal vein thrombosis: a visual analysis_Chinese Journal of Evidence-Based Medicine

Authors：

JIANG Siyu ^1,2 , HUANG Xiaoquan ^1,2 ,  CHEN Shiyao ^1,2,3

1. Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R.China;
2. Evidence-Based Medicine Center, Fudan University, Shanghai 200032, P.R.China;
3. Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R.China;

Corresponding author：

CHEN Shiyao, Email: Chen.shiyao@zs-hospital.sh.cn

Keywords：

Portal vein thrombosis; Cirrhosis; Anticoagulation; Bibliometric

DOI：

10.7507/1672-2531.202008137

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the hotspots and frontiers and to reveal research trends of cirrhosis with portal vein thrombosis (PVT) by visual analysis.Methods We explored the distributions, key citations and research trends of articles on cirrhosis with PVT published from 1991 to 2020 by citation analysis, co-word analysis, and burst detection by information visual software CiteSpace.Results The quantity of articles on cirrhosis with PVT had been increasing over time. The management of PVT remained the hotspots, while the efficacy and prognosis of anticoagulation of PVT as well as the risk factors and underlying mechanisms of PVT had been frontiers in recent years.Conclusions Anticoagulation and risk factors have been hotspots and frontiers in recent years.

Citation： JIANG Siyu, HUANG Xiaoquan, CHEN Shiyao. Hotspots and frontiers of cirrhosis with portal vein thrombosis: a visual analysis. Chinese Journal of Evidence-Based Medicine, 2021, 21(3): 298-302. doi: 10.7507/1672-2531.202008137 Copy

1.	Tsochatzis EA, Senzolo M, Germani G, et al. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther, 2010, 31(3): 366-374.
2.	Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology, 2019, 156(6): 1582-1599.
3.	Chen CM. CiteSpace Ⅱ: Detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Tec, 2006, 57(3): 359-377.
4.	Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology, 2012, 143(5): 1253-1260.
5.	Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol, 2009, 51(4): 682-689.
6.	Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol, 2010, 44(6): 448-451.
7.	Englesbe MJ, Kubus J, Muhammad W, et al. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl, 2010, 16(1): 83-90.
8.	Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol, 2012, 10(7): 776-783.
9.	Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol, 2004, 40(5): 736-741.
10.	Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1, 243 patients with cirrhosis: results of a longitudinal study. Hepatology, 2015, 61(2): 660-667.
11.	Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology, 2009, 137(6): 2105-2111.
12.	Luca A, Miraglia R, Caruso S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut, 2011, 60(6): 846-852.
13.	Han G, Qi X, He C, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol, 2011, 54(1): 78-88.
14.	Lefrançois C, Derlon A, Le Querrec A, et al. Mesentric venous thrombosis. Risk factors, treatment and outcome. An analysis of 18 cases. Ann Fr Anesth Reanim, 1994, 13(2): 182-194.
15.	Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut, 2005, 54(5): 691-697.
16.	DeLeve LD, Valla DC, Garcia-Tsao G, et al. Vascular disorders of the liver. Hepatology, 2009, 49(5): 1729-1764.
17.	Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol, 2014, 11(7): 435-446.
18.	Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol, 2019, 113: 86-91.
19.	Nagaoki Y, Aikata H, Daijyo K, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res, 2018, 48(1): 51-58.
20.	Radosevich PM, Ring EJ, LaBerge JM, et al. Transjugular intrahepatic portosystemic shunts in patients with portal vein occlusion. Radiology, 1993, 186(2): 523-527.
21.	Rodrigues SG, Sixt S, Abraldes JG, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther, 2019, 49(1): 20-30.
22.	Thornburg B, Desai K, Hickey R, et al. Pretransplantation portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: final analysis of a 61-patient cohort. J Vasc Interv Radiol, 2017, 28(12): 1714-1721.
23.	Zhu K, Meng X, Zhou B, et al. Percutaneous transsplenic portal vein catheterization: technical procedures, safety, and clinical applications. J Vasc Interv Radiol, 2013, 24(4): 518-527.
24.	Bizollon T, Bissuel F, Detry L, et al. Fibrinolytic therapy for portal vein thrombosis. Lancet, 1991, 337(8754): 1416.
25.	De Santis A, Moscatelli R, Catalano C, et al. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: a pilot study. Dig Liver Dis, 2010, 42(6): 451-455.

1. Tsochatzis EA, Senzolo M, Germani G, et al. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther, 2010, 31(3): 366-374.
2. Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology, 2019, 156(6): 1582-1599.
3. Chen CM. CiteSpace Ⅱ: Detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Tec, 2006, 57(3): 359-377.
4. Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology, 2012, 143(5): 1253-1260.
5. Zocco MA, Di Stasio E, De Cristofaro R, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol, 2009, 51(4): 682-689.
6. Amitrano L, Guardascione MA, Menchise A, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol, 2010, 44(6): 448-451.
7. Englesbe MJ, Kubus J, Muhammad W, et al. Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl, 2010, 16(1): 83-90.
8. Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol, 2012, 10(7): 776-783.
9. Amitrano L, Guardascione MA, Brancaccio V, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol, 2004, 40(5): 736-741.
10. Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1, 243 patients with cirrhosis: results of a longitudinal study. Hepatology, 2015, 61(2): 660-667.
11. Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology, 2009, 137(6): 2105-2111.
12. Luca A, Miraglia R, Caruso S, et al. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut, 2011, 60(6): 846-852.
13. Han G, Qi X, He C, et al. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis. J Hepatol, 2011, 54(1): 78-88.
14. Lefrançois C, Derlon A, Le Querrec A, et al. Mesentric venous thrombosis. Risk factors, treatment and outcome. An analysis of 18 cases. Ann Fr Anesth Reanim, 1994, 13(2): 182-194.
15. Francoz C, Belghiti J, Vilgrain V, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut, 2005, 54(5): 691-697.
16. DeLeve LD, Valla DC, Garcia-Tsao G, et al. Vascular disorders of the liver. Hepatology, 2009, 49(5): 1729-1764.
17. Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol, 2014, 11(7): 435-446.
18. Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol, 2019, 113: 86-91.
19. Nagaoki Y, Aikata H, Daijyo K, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res, 2018, 48(1): 51-58.
20. Radosevich PM, Ring EJ, LaBerge JM, et al. Transjugular intrahepatic portosystemic shunts in patients with portal vein occlusion. Radiology, 1993, 186(2): 523-527.
21. Rodrigues SG, Sixt S, Abraldes JG, et al. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther, 2019, 49(1): 20-30.
22. Thornburg B, Desai K, Hickey R, et al. Pretransplantation portal vein recanalization and transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: final analysis of a 61-patient cohort. J Vasc Interv Radiol, 2017, 28(12): 1714-1721.
23. Zhu K, Meng X, Zhou B, et al. Percutaneous transsplenic portal vein catheterization: technical procedures, safety, and clinical applications. J Vasc Interv Radiol, 2013, 24(4): 518-527.
24. Bizollon T, Bissuel F, Detry L, et al. Fibrinolytic therapy for portal vein thrombosis. Lancet, 1991, 337(8754): 1416.
25. De Santis A, Moscatelli R, Catalano C, et al. Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: a pilot study. Dig Liver Dis, 2010, 42(6): 451-455.

Previous Article
Hotspots and frontiers of oral lichen planus research: a visual analysis
Next Article
Analysis of the application of randomization methods in clinical trials in NEJM

Chinese Journal of Evidence-Based Medicine

Hotspots and frontiers of cirrhosis with portal vein thrombosis: a visual analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content